Sign in

    Matt [Analyst]Alliance Global Partners

    Matt [Analyst]'s questions to TAT Technologies Ltd (TATT) leadership

    Matt [Analyst]'s questions to TAT Technologies Ltd (TATT) leadership • Q1 2025

    Question

    Matt [Analyst] inquired about the sources of recent business growth, the drivers behind gross margin expansion, the company's strategy for managing persistent supply chain issues, and its current operational capacity.

    Answer

    Executive Igal Zamir clarified that growth stems from a mix of new and existing customers across various business lines. He attributed the significant margin improvement to major operational efficiency initiatives, not pricing, stating a long-term goal of at least 25% gross margin. To counter supply chain volatility, Zamir confirmed a strategic increase in inventory, viewing it as a competitive advantage that ensures high service levels. He also stated that due to past investments, TAT has the facility and equipment capacity to more than double its output, with the supply chain being the primary constraint.

    Ask Fintool Equity Research AI

    Matt [Analyst]'s questions to Aquestive Therapeutics Inc (AQST) leadership

    Matt [Analyst]'s questions to Aquestive Therapeutics Inc (AQST) leadership • Q1 2025

    Question

    Matt [Analyst] of Alliance Global Partners asked for an assessment of the current ex-U.S. partnership environment for Anaphylm and inquired about the potential timeline for reprioritizing the AQST-108 clinical program.

    Answer

    CEO Daniel Barber characterized the ex-U.S. partnership environment as 'active,' noting competitor deals and ongoing discussions with interested parties. Regarding AQST-108, he reiterated his belief in the product but confirmed it is being deprioritized to free up capital for the Anaphylm launch. He stated the goal is to return to it as soon as possible, but not at the expense of a successful Anaphylm launch, suggesting a post-launch timeframe.

    Ask Fintool Equity Research AI